MTOR and bone neoplasm: mTOR inhibition compromised CSC traits [85, 86] by modulating mitochondrial function in several types of cancers, such as pancreatic, ovarian, and bone cancers [82, 87–89], suggesting that the YY1-mTOR-PGC-1α axis plays the key role in the biology of CSCs.